Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $7,150 | 1 | 85.0% |
| Travel and Lodging | $1,058 | 4 | 12.6% |
| Food and Beverage | $200.53 | 3 | 2.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GlaxoSmithKline, LLC. | $8,272 | 6 | $0 (2020) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $111.90 | 1 | $0 (2019) |
| ABIOMED | $24.88 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $24.88 | 1 | ABIOMED ($24.88) |
| 2020 | $8,272 | 6 | GlaxoSmithKline, LLC. ($8,272) |
| 2019 | $111.90 | 1 | Boehringer Ingelheim Pharmaceuticals, Inc. ($111.90) |
All Payment Transactions
8 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/27/2023 | ABIOMED | Impella (Device) | Food and Beverage | In-kind items and services | $24.88 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 04/21/2020 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Consulting Fee | Cash or cash equivalent | $7,150.00 | General |
| Category: RESPIRATORY | ||||||
| 04/21/2020 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Travel and Lodging | Cash or cash equivalent | $80.64 | General |
| Category: RESPIRATORY | ||||||
| 02/11/2020 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $63.75 | General |
| 02/10/2020 | GlaxoSmithKline, LLC. | — | Travel and Lodging | In-kind items and services | $31.50 | General |
| 02/08/2020 | GlaxoSmithKline, LLC. | — | Travel and Lodging | In-kind items and services | $769.58 | General |
| 02/08/2020 | GlaxoSmithKline, LLC. | — | Travel and Lodging | In-kind items and services | $176.03 | General |
| 03/21/2019 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $111.90 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2022 | 1 | 12 | 16 | $12,464 | $2,771 |
| 2021 | 1 | 11 | 13 | $10,647 | $2,296 |
All Medicare Procedures & Services
2 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 12 | 16 | $12,464 | $2,771 | 22.2% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2021 | 11 | 13 | $10,647 | $2,296 | 21.6% |
About Richard Mularski, MD, MCR, MSHS
Richard Mularski, MD, MCR, MSHS is a Pulmonary Disease healthcare provider based in Clackamas, Oregon. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/30/2006. The National Provider Identifier (NPI) number assigned to this provider is 1780699256.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Richard Mularski, MD, MCR, MSHS has received a total of $8,408 in payments from pharmaceutical and medical device companies, with $24.88 received in 2023. These payments were reported across 8 transactions from 3 companies. The most common payment nature is "Consulting Fee" ($7,150).
As a Medicare-enrolled provider, Mularski has provided services to 23 Medicare beneficiaries, totaling 29 services with total Medicare billing of $5,068. Data is available for 2 years (2021–2022), covering 2 distinct procedure/service records.
Practice Information
- Specialty Pulmonary Disease
- Location Clackamas, OR
- Active Since 07/30/2006
- Last Updated 07/09/2007
- Taxonomy Code 207RP1001X
- Entity Type Individual
- NPI Number 1780699256
Products in Payments
- TRELEGY ELLIPTA (Drug) $7,231
- Impella (Device) $24.88
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.